TY - JOUR
T1 - Impaired antigen-specific lymphocyte priming in mice after Toll-like receptor 4 activation via induction of monocytic myeloid-derived suppressor cells
AU - Tsukamoto, Hiroki
AU - Kozakai, Sao
AU - Kobayashi, Yohei
AU - Takanashi, Risako
AU - Aoyagi, Takuya
AU - Numasaki, Muneo
AU - Ohta, Shoichiro
AU - Tomioka, Yoshihisa
N1 - Funding Information:
Acknowledgments: We thank Dr. N. Ishii for providing us with OT-I and –II mice. We thank Ms. Kanae Kubota and Ms. Ayumi Shichiku in our laboratory for the assistance of experiments. This work was supported in part by JSPS KAKENHI grant numbers 26460058 and 18K06651 (HT), grants provided by the Suzuken Memorial Foundation (HT), and the Japan Diabetes Foundation (HT). H.T. conceived and supervised the study; H.T. and S.K. designed and performed experiments; Y.K., R.T., and T.A. performed experiments; H.T. wrote the manuscript; M.N., S.O., and Y.T. reviewed the manuscript. All authors approved the final version of the manuscript.
PY - 2019/4
Y1 - 2019/4
N2 - In sepsis, the pathology involves a shift from a proinflammatory state toward an immunosuppressive phase. We previously showed that an agonistic anti-TLR4 antibody induced long-term endotoxin tolerance and suppressed antigen-specific secondary IgG production when primed prior to immunization with antigen. These findings led us to speculate that TLR4-induced innate tolerance due to primary infection causes an immunosuppressive pathology in sepsis. Therefore, the mechanism underlying impaired antigen-specific humoral immunity by the TLR4 antibody was investigated. We showed, in a mouse model, that primary antigen-specific IgG responses were impaired in TLR4 antibody-induced tolerized mice, which was the result of reduced numbers of antigen-specific GC B cells and plasma cells. Ovalbumin-specific CD4 and CD8 T-cell responses were impaired in TLR4 antibody-injected OT-I and -II transgenic mice ex vivo. Adoptive transfer studies demonstrated suppression of OVA-specific CD4 and CD8 T-cell responses by the TLR4 antibody in vivo. The TLR4 antibody induced Gr1 + CD11b + myeloid-derived suppressor cell (MDSC) expansion with suppression of T-cell activation. Monocytic MDSCs were more suppressive and exhibited higher expression of PD-L1 and inducible nitric oxidase compared with granulocytic MDSCs. In conclusion, immune tolerance conferred by TLR4 activation induces the expansion of monocytic MDSCs, which impairs antigen-specific T-cell priming and IgG production.
AB - In sepsis, the pathology involves a shift from a proinflammatory state toward an immunosuppressive phase. We previously showed that an agonistic anti-TLR4 antibody induced long-term endotoxin tolerance and suppressed antigen-specific secondary IgG production when primed prior to immunization with antigen. These findings led us to speculate that TLR4-induced innate tolerance due to primary infection causes an immunosuppressive pathology in sepsis. Therefore, the mechanism underlying impaired antigen-specific humoral immunity by the TLR4 antibody was investigated. We showed, in a mouse model, that primary antigen-specific IgG responses were impaired in TLR4 antibody-induced tolerized mice, which was the result of reduced numbers of antigen-specific GC B cells and plasma cells. Ovalbumin-specific CD4 and CD8 T-cell responses were impaired in TLR4 antibody-injected OT-I and -II transgenic mice ex vivo. Adoptive transfer studies demonstrated suppression of OVA-specific CD4 and CD8 T-cell responses by the TLR4 antibody in vivo. The TLR4 antibody induced Gr1 + CD11b + myeloid-derived suppressor cell (MDSC) expansion with suppression of T-cell activation. Monocytic MDSCs were more suppressive and exhibited higher expression of PD-L1 and inducible nitric oxidase compared with granulocytic MDSCs. In conclusion, immune tolerance conferred by TLR4 activation induces the expansion of monocytic MDSCs, which impairs antigen-specific T-cell priming and IgG production.
KW - Endotoxin tolerance
KW - Innate immunity
KW - Myeloid-derived suppressor cells
KW - Sepsis
KW - TLR 4
UR - http://www.scopus.com/inward/record.url?scp=85060929649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060929649&partnerID=8YFLogxK
U2 - 10.1002/eji.201847805
DO - 10.1002/eji.201847805
M3 - Article
C2 - 30671932
AN - SCOPUS:85060929649
VL - 49
SP - 546
EP - 563
JO - European Journal of Immunology
JF - European Journal of Immunology
SN - 0014-2980
IS - 4
ER -